ArticleFrontiers in public health2022

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.

Jianzhou Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.